Cite
HARVARD Citation
Corrie, P. et al. (2019). A prospective observational safety study of patients with BRAFV600‐mutated unresectable or metastatic melanoma treated with vemurafenib (Zelboraf Safety Study). British journal of dermatology. pp. 1254-1255. [Online].